We use cookies for a better user experience. Read our Privacy Policy

I Agree

Industry Verticals »

All Categories

Insights »

About TMR »

Proliferative Diabetic Retinopathy Market

Schedule a Call

Proliferative Diabetic Retinopathy Market

Proliferative Diabetic Retinopathy Market (Drug Class - Anti-VEGF Agents, and Corticosteroids; Mode of Administration - Injectables, Oral, and Others; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2026

As a consequence of the pandemic of type 2 diabetes, an outbreak of several diabetic complications, particularly diabetic retinopathy is foreseen by several healthcare institutions and pharmaceutical companies across the globe. Among complications of diabetic retinopathy, proliferative diabetic retinopathy has witnessed a relatively more significant surge worldwide. For example, roughly 1.5% adults suffering from diabetes were affected from proliferative diabetic retinopathy in the U.S. in the recent past.

Although molecular and cellular bases of the proliferative diabetic retinopathy have only been partially understood, complication of diabetes is evidently characterized by formation of new vessels inside retina that depicts abnormal architecture and permeability. Angiogenesis is considered to have a major role in pathogenesis of proliferative diabetic retinopathy, with intravitreal antiangiogenic injection being suggested by researchers and drug developers as a viable treatment for the disease. Different antiangiogenic approaches are being employed for developing effective treatment of proliferative diabetic retinopathy, which in turn are likely to have imperative roles for therapy & prevention of the disease in the upcoming years.

global proliferative diabetic retinopathy market

A recently composed research report of Transparency Market Research has envisaged the global market for proliferative diabetic retinopathy to register a high single-digit CAGR through the forecast period (2017-2026). Revenues from treatment of proliferative diabetic retinopathy around the world are poised to reach roughly US$ 1,000 Mn by 2026-end.

Anti-VEGF Considered as Effective Management Method for Proliferative Diabetic Retinopathy

According to the National Center for Biotechnology Information (NCBI), over 150 Mn individuals were affected by diabetic retinopathy globally, with majority of them at the risk of developing proliferative diabetic retinopathy. Such rapid rise in the number of people with this diseases will increase the scope of its treatment & prevention. Across countries with relatively less availability of treatment facilities, demand and supply of effective treatment drugs have been witnessing a tremendous surge.

Recent studies suggest high level of the vascular endothelial growth factor (VEGF) being detected in fibrovascular tissues of eyes of diabetic patients has prompted use of anti-VEGF as the most effective and efficient management method, in cases of proliferative diabetic retinopathy. Introduction and robust adoption of the intravitreal pharmacologic agents, especially drugs that inhibit actions of VEGF, have directed the focus of approach toward proliferative diabetic retinopathy treatment from vision stabilization to improvement. Improvements in visual acuity of patients with this diseases by using anti-VEGF are comparatively more effective than improvements observed in treatment by using corticosteroids.

Growth in Geriatric Population to be a Key Demand Determinant of Drugs for Proliferative Diabetic Retinopathy Treatment

Geriatric populace across the globe has been exhibiting a significant increase, and this demographic group is highly susceptible to various chronic disorders such as diabetes. Proliferative diabetic retinopathy development is therefore more prevalent among the elder individuals. Cases of this diseases are deemed to be multifold in patients who are above 65 years old and have a diabetic history. This has further driven the demand for effective drugs for management of proliferative diabetic retinopathy in older population.

The rise in disposable income of consumers, coupled with concerns regarding vision loss has rubbed off on spending by patients for availing necessary treatment of diabetic retinopathy. Availability of advanced technology & minimally invasive laser technique that complements faster recovery time is likely to encourage willingness of patients affected from proliferative diabetic retinopathy in adopting surgical treatments.

Key companies significantly contributing to growth of the global proliferative diabetic retinopathy market include Intas Pharmaceuticals Limited, Santen Pharmaceutical Co., Ltd., Valeant Pharmaceuticals International, Inc., Allergan Plc, Regeneron Pharmaceuticals, Inc., Merck KGaA, Cipla, Ltd., Genentech, Inc. (Roche Holdings), Novartis AG, and Pfizer, Inc.

Heightening Cases of Long-term Diabetes to Influence Growth of Proliferative Diabetic Retinopathy Market

Diabetes has been a problem for many decades and causes great loss of lives throughout the year. A large number of people are diagnosed with diabetes. According to the International Diabetes Federation, nearly 463 mn adults were living with diabetes and the number will rise to 700 mn by 2045. Diabetes brings a wide range of diseases and disorders.

  • Diabetic retinopathy is one of the vital complications associated with long-term diabetes. Proliferative diabetic retinopathy is a sub-type of diabetic retinopathy with a larger case-rate worldwide. Thus, the growing threat of proliferative diabetic retinopathy will invite promising growth for the proliferative diabetic retinopathy market during the forecast period of 2017-2026.
  • The rising numbers across the geriatric population have brought tremendous growth opportunities for the proliferative diabetic retinopathy market. The geriatric populace is more susceptible to chronic diseases and thus, this aspect may further enhance the growth prospects of the proliferative diabetic retinopathy market.
  • The availability of advanced healthcare technologies and minimally invasive laser technique will have a massive impact on the growth of the proliferative diabetic retinopathy market. In addition, the rise in the disposable income of consumers will strengthen the growth of the proliferative diabetic retinopathy market to a great extent. Escalating concerns regarding vision loss will further help the proliferative diabetic retinopathy market to gain profitable growth.
  • The novel coronavirus pandemic has affected the proliferative diabetic retinopathy market to a certain extent. The outbreak has completely changed the growth dynamics of various businesses and sectors. The border restrictions and the stringent stay-at-home orders have disrupted the supply chain mechanisms extensively. Thus, all these aspects have negatively influenced the growth of the proliferative diabetic retinopathy market. However, the easing of lockdown restrictions presents a good opportunity for the players in the proliferative diabetic retinopathy market to regain lost growth.

Market Taxonomy

Region
  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA

Drug Class
  • Anti-VEGF Agents
  • Corticosteroids

Mode of Administration
  • Injectables
  • Oral
  • Others

Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

    1. Global Economic Outlook

    2. Global Proliferative Diabetic Retinopathy Market - Executive Summary

    3. Global Proliferative Diabetic Retinopathy Market Overview
         3.1. Introduction
                3.1.1. Global Proliferative Diabetic Retinopathy Market Taxonomy
                3.1.2. Global Proliferative Diabetic Retinopathy Market Definition
         3.2. Global Proliferative Diabetic Retinopathy Market Size (US$ Mn) and Forecast, 2012-2026
                3.2.1. Global Proliferative Diabetic Retinopathy Market Y-o-Y Growth
         3.3. Global Proliferative Diabetic Retinopathy Market Dynamics
         3.4. Supply Chain
         3.5. Cost Structure
         3.6. Average Pricing Analysis
         3.7. Forecast Scenario
         3.8. Parent Market Overview
         3.9. Product Approvals in Proliferative Diabetic Retinopathy
         3.10. PATENT Analysis
         3.11. Porter's Five Forces Analysis
         3.12. Epidemiology
         3.13. Investment Feasibility Index
         3.14. Market Competition Structure
         3.15. PEST Analysis
         3.16. Market Positioning & Behavior Assessment
         3.17. List of Distributors
         3.18. Key Participants Market Presence (Intensity Map) By Region

    4. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast 2012-2026
         4.1. Global Proliferative Diabetic Retinopathy Market Size and Forecast By Drug Class, 2012-2026
                4.1.1. Anti-VEGF Agents Market Size and Forecast, 2012-2026
                         4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.1.2. Market Share Comparison, By Region
                         4.1.1.3. Y-o-Y growth Comparison, By Region
                4.1.2. Corticosteroids Market Size and Forecast, 2012-2026
                         4.1.2.1. Revenue (US$ Mn) Comparison, By Region
                         4.1.2.2. Market Share Comparison, By Region
                         4.1.2.3. Y-o-Y growth Comparison, By Region
         4.2. Global Proliferative Diabetic Retinopathy Market Size and Forecast By Mode of Administration, 2012-2026
                4.2.1. Injectables Market Size and Forecast, 2012-2026
                         4.2.1.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.1.2. Market Share Comparison, By Region
                         4.2.1.3. Y-o-Y growth Comparison, By Region
                4.2.2. Oral Market Size and Forecast, 2012-2026
                         4.2.2.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.2.2. Market Share Comparison, By Region
                         4.2.2.3. Y-o-Y growth Comparison, By Region
                4.2.3. Others Market Size and Forecast, 2012-2026
                         4.2.3.1. Revenue (US$ Mn) Comparison, By Region
                         4.2.3.2. Market Share Comparison, By Region
                         4.2.3.3. Y-o-Y growth Comparison, By Region
         4.3. Global Proliferative Diabetic Retinopathy Market Size and Forecast By Distribution Channel, 2012-2026
                4.3.1. Hospital Pharmacies Market Size and Forecast, 2012-2026
                         4.3.1.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.1.2. Market Share Comparison, By Region
                         4.3.1.3. Y-o-Y growth Comparison, By Region
                4.3.2. Retail Pharmacies Market Size and Forecast, 2012-2026
                         4.3.2.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.2.2. Market Share Comparison, By Region
                         4.3.2.3. Y-o-Y growth Comparison, By Region
                4.3.3. Online Pharmacies Market Size and Forecast, 2012-2026
                         4.3.3.1. Revenue (US$ Mn) Comparison, By Region
                         4.3.3.2. Market Share Comparison, By Region
                         4.3.3.3. Y-o-Y growth Comparison, By Region

    5. North America Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
         5.1. North America Outlook
         5.2. North America Parent Market Outlook
         5.3. North America Target Market Outlook
         5.4. Revenue (US$ Mn) Comparison, By Country
                5.4.1. US Market Size and Forecast (US$ Mn), 2012-2026
                5.4.2. Canada Market Size and Forecast (US$ Mn), 2012-2026
         5.5. Revenue (US$ Mn) Comparison, By Drug Class
         5.6. Revenue (US$ Mn) Comparison, By Mode of Administration
         5.7. Revenue (US$ Mn) Comparison, By Distribution Channel

    6. Latin America Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
         6.1. Latin America Outlook
         6.2. Latin America Parent Market Outlook
         6.3. Latin America Target Market Outlook
         6.4. Revenue (US$ Mn) Comparison, By Country
                6.4.1. Brazil Market Size and Forecast (US$ Mn), 2012-2026
                6.4.2. Mexico Market Size and Forecast (US$ Mn), 2012-2026
                6.4.3. Rest of Latin America Market Size and Forecast (US$ Mn), 2012-2026
         6.5. Revenue (US$ Mn) Comparison, By Drug Class
         6.6. Revenue (US$ Mn) Comparison, By Mode of Administration
         6.7. Revenue (US$ Mn) Comparison, By Distribution Channel

    7. Europe Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
         7.1. Europe Outlook
         7.2. Europe Parent Market Outlook
         7.3. Europe Target Market Outlook
         7.4. Revenue (US$ Mn) Comparison, By Country
                7.4.1. Germany Market Size and Forecast (US$ Mn), 2012-2026
                7.4.2. U.K. Market Size and Forecast (US$ Mn), 2012-2026
                7.4.3. Spain Market Size and Forecast (US$ Mn), 2012-2026
                7.4.4. France Market Size and Forecast (US$ Mn), 2012-2026
                7.4.5. Italy Market Size and Forecast (US$ Mn), 2012-2026
                7.4.6. Rest of Europe Market Size and Forecast (US$ Mn), 2012-2026
         7.5. Revenue (US$ Mn) Comparison, By Drug Class
         7.6. Revenue (US$ Mn) Comparison, By Mode of Administration
         7.7. Revenue (US$ Mn) Comparison, By Distribution Channel

    8. Japan Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
         8.1. Japan Outlook
         8.2. Japan Parent Market Outlook
         8.3. Japan Target Market Outlook
         8.4. Japan  Market Size and Forecast (US$ Mn), 2012-2026
         8.5. Revenue (US$ Mn) Comparison, By Drug Class
         8.6. Revenue (US$ Mn) Comparison, By Mode of Administration
         8.7. Revenue (US$ Mn) Comparison, By Distribution Channel

    9. APEJ Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
         9.1. APEJ Outlook
         9.2. APEJ Parent Market Outlook
         9.3. APEJ Target Market Outlook
         9.4. Revenue (US$ Mn) Comparison, By Country
                9.4.1. China Market Size and Forecast (US$ Mn), 2012-2026
                9.4.2. India Market Size and Forecast (US$ Mn), 2012-2026
                9.4.3. Malaysia Market Size and Forecast (US$ Mn), 2012-2026
                9.4.4. Singapore Market Size and Forecast (US$ Mn), 2012-2026
                9.4.5. Australia Market Size and Forecast (US$ Mn), 2012-2026
                9.4.6. Rest of APEJ Market Size and Forecast (US$ Mn), 2012-2026
         9.5. Revenue (US$ Mn) Comparison, By Drug Class
         9.6. Revenue (US$ Mn) Comparison, By Mode of Administration
         9.7. Revenue (US$ Mn) Comparison, By Distribution Channel

    10. MEA Proliferative Diabetic Retinopathy Market Size and Forecast, 2012-2026
         10.1. MEA Outlook
         10.2. MEA Parent Market Outlook
         10.3. MEA Target Market Outlook
         10.4. Revenue (US$ Mn) Comparison, By Country
                10.4.1. GCC Countries Market Size and Forecast (US$ Mn), 2012-2026
                10.4.2. South Africa Market Size and Forecast (US$ Mn), 2012-2026
                10.4.3. Israel Market Size and Forecast (US$ Mn), 2012-2026
                10.4.4. Rest of MEA Market Size and Forecast (US$ Mn), 2012-2026
         10.5. Revenue (US$ Mn) Comparison, By Drug Class
         10.6. Revenue (US$ Mn) Comparison, By Mode of Administration
         10.7. Revenue (US$ Mn) Comparison, By Distribution Channel

    11. Global Proliferative Diabetic Retinopathy Market Company Share, Competition Landscape and Company Profiles
         11.1. Global Proliferative Diabetic Retinopathy Market - Company Share Analysis
         11.2. Global Proliferative Diabetic Retinopathy Market - Competition Landscape
         11.3. Global Proliferative Diabetic Retinopathy Market - Company Profiles
                11.3.1. Genentech, Inc. (Roche Holdings)
                11.3.2. Novartis AG
                11.3.3. Regeneron Pharmaceuticals, Inc.
                11.3.4. Pfizer, Inc.
                11.3.5. Merck KGaA
                11.3.6. Cipla, Ltd.
                11.3.7. Allergan Plc
                11.3.8. Valeant Pharmaceuticals International, Inc.
                11.3.9. Santen Pharmaceutical Co., Ltd.
                11.3.10. Alimera Sciences, Inc.
                11.3.11. Intas Pharmaceuticals Limited

    12. Global Proliferative Diabetic Retinopathy Market - Key Takeaways

    13. Research Methodology

    14. Disclaimer

     

    List of Table

    TABLE 1 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn), 2012-2017
    TABLE 2 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn), 2018-2026
    TABLE 3 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn) and Y-o-Y, 2017-2026
    TABLE 4 Global Anti-VEGF Agents Segment Value (US$ Mn), By Region 2012-2017
    TABLE 5 Global Anti-VEGF Agents Segment Value (US$ Mn), By Region 2018-2026
    TABLE 6 Global Anti-VEGF Agents Segment Market Share, By Region 2012-2017
    TABLE 7 Global Anti-VEGF Agents Segment Market Share, By Region 2018-2026
    TABLE 8 Global Anti-VEGF Agents Segment Y-o-Y, By Region 2017-2026
    TABLE 9 Global Corticosteroids Segment Value (US$ Mn), By Region 2012-2017
    TABLE 10 Global Corticosteroids Segment Value (US$ Mn), By Region 2018-2026
    TABLE 11 Global Corticosteroids Segment Market Share, By Region 2012-2017
    TABLE 12 Global Corticosteroids Segment Market Share, By Region 2018-2026
    TABLE 13 Global Corticosteroids Segment Y-o-Y, By Region 2017-2026
    TABLE 14 Global Injectables Segment Value (US$ Mn), By Region 2012-2017
    TABLE 15 Global Injectables Segment Value (US$ Mn), By Region 2018-2026
    TABLE 16 Global Injectables Segment Market Share, By Region 2012-2017
    TABLE 17 Global Injectables Segment Market Share, By Region 2018-2026
    TABLE 18 Global Injectables Segment Y-o-Y, By Region 2017-2026
    TABLE 19 Global Oral Segment Value (US$ Mn), By Region 2012-2017
    TABLE 20 Global Oral Segment Value (US$ Mn), By Region 2018-2026
    TABLE 21 Global Oral Segment Market Share, By Region 2012-2017
    TABLE 22 Global Oral Segment Market Share, By Region 2018-2026
    TABLE 23 Global Oral Segment Y-o-Y, By Region 2017-2026
    TABLE 24 Global Others Segment Value (US$ Mn), By Region 2012-2017
    TABLE 25 Global Others Segment Value (US$ Mn), By Region 2018-2026
    TABLE 26 Global Others Segment Market Share, By Region 2012-2017
    TABLE 27 Global Others Segment Market Share, By Region 2018-2026
    TABLE 28 Global Others Segment Y-o-Y, By Region 2017-2026
    TABLE 29 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
    TABLE 30 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
    TABLE 31 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
    TABLE 32 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
    TABLE 33 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
    TABLE 34 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
    TABLE 35 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
    TABLE 36 Global Retail Pharmacies Segment Market Share, By Region 2012-2017
    TABLE 37 Global Retail Pharmacies Segment Market Share, By Region 2018-2026
    TABLE 38 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
    TABLE 39 Global Online Pharmacies Segment Value (US$ Mn), By Region 2012-2017
    TABLE 40 Global Online Pharmacies Segment Value (US$ Mn), By Region 2018-2026
    TABLE 41 Global Online Pharmacies Segment Market Share, By Region 2012-2017
    TABLE 42 Global Online Pharmacies Segment Market Share, By Region 2018-2026
    TABLE 43 Global Online Pharmacies Segment Y-o-Y, By Region 2017-2026
    TABLE 44 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    TABLE 45 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    TABLE 46 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    TABLE 47 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    TABLE 48 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    TABLE 49 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    TABLE 50 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 51 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 52 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    TABLE 53 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    TABLE 54 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    TABLE 55 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    TABLE 56 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    TABLE 57 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    TABLE 58 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 59 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 60 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    TABLE 61 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    TABLE 62 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    TABLE 63 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    TABLE 64 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    TABLE 65 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    TABLE 66 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 67 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 68 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    TABLE 69 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    TABLE 70 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    TABLE 71 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    TABLE 72 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    TABLE 73 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    TABLE 74 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 75 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 76 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    TABLE 77 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    TABLE 78 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    TABLE 79 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    TABLE 80 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    TABLE 81 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    TABLE 82 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 83 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
    TABLE 84 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    TABLE 85 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    TABLE 86 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    TABLE 87 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    TABLE 88 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    TABLE 89 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    TABLE 90 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    TABLE 91 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026

     

    List of Figure

    FIG. 1 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn), 2012-2017
    FIG. 2 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn) Forecast, 2018-2026
    FIG. 3 Global Proliferative Diabetic Retinopathy Market Value (US$ Mn) and Y-o-Y, 2017-2026
    FIG. 4 Global Anti-VEGF Agents Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 5 Global Anti-VEGF Agents Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 6 Global Anti-VEGF Agents Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 7 Global Corticosteroids Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 8 Global Corticosteroids Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 9 Global Corticosteroids Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 10 Global Injectables Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 11 Global Injectables Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 12 Global Injectables Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 13 Global Oral Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 14 Global Oral Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 15 Global Oral Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 16 Global Others Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 17 Global Others Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 18 Global Others Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 19 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 20 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 21 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 22 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 23 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 24 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 25 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
    FIG. 26 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
    FIG. 27 Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
    FIG. 28 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    FIG. 29 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    FIG. 30 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    FIG. 31 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    FIG. 32 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    FIG. 33 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    FIG. 34 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 35 North America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 36 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    FIG. 37 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    FIG. 38 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    FIG. 39 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    FIG. 40 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    FIG. 41 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    FIG. 42 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 43 Latin America Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 44 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    FIG. 45 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    FIG. 46 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    FIG. 47 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    FIG. 48 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    FIG. 49 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    FIG. 50 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 51 Europe Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 52 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    FIG. 53 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    FIG. 54 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    FIG. 55 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    FIG. 56 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 57 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    FIG. 58 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 59 Japan Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 60 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    FIG. 61 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    FIG. 62 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    FIG. 63 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    FIG. 64 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    FIG. 65 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    FIG. 66 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 67 APEJ Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026
    FIG. 68 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2012-2017
    FIG. 69 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Country 2018-2026
    FIG. 70 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2012-2017
    FIG. 71 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Drug Class 2018-2026
    FIG. 72 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2012-2017
    FIG. 73 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Mode of Administration 2018-2026
    FIG. 74 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2012-2017
    FIG. 75 MEA Proliferative Diabetic Retinopathy Market Value (US$ Mn), By Distribution Channel 2018-2026

Copyright © Transparency Market Research, Inc. All Rights reserved